Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6300 in Advanced Solid Tumors and Soft Tissue Sarcoma
NCT03168061Phase 2Unknown
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NC-6300 in solid tumor (advanced stage) and soft tissue sarcoma (STS), sponsored by NanoCarrier Co., Ltd. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Status: unknown.
02
Drugs
NC-6300
03
Conditions
solid tumor (advanced stage)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03168061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168061.